Cargando…

Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways

BACKGROUND AND PURPOSE: The intraocular pressure (IOP)-lowering and side effects in response to different prostaglandin F(2)α analogues can be variable, but, the underlying basis for this difference remains unknown. This study investigated the differential changes of cellular proteins relevant to IO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaohong, He, Fen, Gabelt, B’Ann T., Wang, Yun, Cai, Suping, Cao, Juanhui, Fan, Ning, Kaufman, Paul L., Liu, Xuyang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807090/ https://www.ncbi.nlm.nih.gov/pubmed/27011234 http://dx.doi.org/10.1371/journal.pone.0151644

Ejemplares similares

Latanoprost PF vs. Bimatoprost PF: Which Treats the Ocular Surface Better?
por: Dimtsas, Georgios S., et al.
Publicado: (2023)

Tear biomarkers in latanoprost and bimatoprost treated eyes
por: Reddy, Shweta, et al.
Publicado: (2018)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG/OHT Patients
por: Cai, Ziyan, et al.
Publicado: (2021)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost
por: Maruyama, Yuko, et al.
Publicado: (2015)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
por: Chen, Wensheng, et al.
Publicado: (2014)

Correction: Corneal Alterations Induced by Topical Application of Commercial Latanoprost, Travoprost and Bimatoprost in Rabbit
Publicado: (2014)

Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases
por: Yamada, Hiroshi, et al.
Publicado: (2016)

Effects of glaucoma drugs on ocular hemodynamics in normal tension glaucoma: a randomized trial comparing bimatoprost and latanoprost with dorzolamide [ISRCTN18873428]
por: Zeitz, Oliver, et al.
Publicado: (2005)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
por: Myers, Jonathan S, et al.
Publicado: (2014)

Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on 24-hour blood and ocular perfusion pressures: the results of a randomized trial
por: Rossetti, Luca, et al.
Publicado: (2015)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Workshop on Inflows, Outflows and Reprocessing around Black Holes
Publicado: (2002)

Diurnal Intraocular Pressure with Bimatoprost/Timolol Fixed Combination versus Latanoprost/Timolol Fixed Combination in Healthy Subjects
por: Shim, Seong Hee, et al.
Publicado: (2014)

Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost
por: García-Feijoo, Julian, et al.
Publicado: (2016)

SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
por: Ashwinbalaji, Soundararajan, et al.
Publicado: (2018)

Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study
por: Kammer, J A, et al.
Publicado: (2010)

Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study
por: Gutierrez-Diaz, Esperanza, et al.
Publicado: (2014)

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
por: Lazzaro, Carlo, et al.
Publicado: (2022)

Migration in Northeast India: Inflows, Outflows and Reverse Flows during Pandemic
por: Lusome, R., et al.
Publicado: (2020)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Retrospective Analysis of Switching Bimatoprost 0.01% to Bimatoprost 0.03% in Patients with Various Types of Glaucoma and Ocular Hypertension
por: Xu, Kai Man, et al.
Publicado: (2022)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Global FDI inflows and outflows in emerging economies Post-COVID-19 era
por: Al-kasasbeh, Omar, et al.
Publicado: (2022)

A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
por: Craven, E Randy, et al.
Publicado: (2010)

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension
por: Pacella, Fernanda, et al.
Publicado: (2012)

Relationship between cerebral arterial inflow and venous outflow during dynamic supine exercise
por: Sato, Kohei, et al.
Publicado: (2017)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Bimatoprost in Dermatology
por: Jha, Abhijeet K., et al.
Publicado: (2018)

Uveitis-induced Refractory Ocular Hypotony Managed with High-dose Latanoprost
por: Ghassemi, Fariba, et al.
Publicado: (2020)

Development of automated postoperative enteral nutrition: restricting feeding site inflow to match peristaltic outflow
por: Moss, Gerald
Publicado: (2015)

Effect of population inflow and outflow between rural and urban areas on regional antimicrobial use surveillance
por: Koizumi, Ryuji, et al.
Publicado: (2021)

Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure–Lowering Effects of Latanoprost
por: Roddy, Gavin W., et al.
Publicado: (2017)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue, Kenji, et al.
Publicado: (2012)

Ocular Delivery of Bimatoprost-Loaded Solid Lipid Nanoparticles for Effective Management of Glaucoma
por: Satyanarayana, Sandeep Divate, et al.
Publicado: (2023)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
por: Smid, Scott D
Publicado: (2009)

Cost–Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany
por: Lazzaro, Carlo, et al.
Publicado: (2022)

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
por: Tokuda, Naoto, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8bmtlq8b9lg1jb73njgpuiakqa